info@brixtonbio.com
Location: United States, Massachusetts, Cambridge
Total raised: $33M
Investors 3
| Date | Name | Website |
| 29.07.2024 | Schooner C... | schoonerca... |
| - | Hub Angels... | hubangels.... |
| - | Catalyst H... | chv.vc |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.05.2024 | Series B | $33M | - |
Mentions in press and media 4
| Date | Title | Description |
| 16.05.2024 | Brixton Biosciences: Leading the Charge in Pain Management Innovation | Brixton Biosciences, a cutting-edge clinical-stage life sciences company, has recently secured a substantial $33 million in Series B funding to propel their groundbreaking work in advancing novel pain therapies. Spearheaded by the visionary... |
| 14.05.2024 | Brixton Biosciences Raises $33M in Series B Funding | Brixton Biosciences, a Cambridge, MA-based clinical stage life sciences company developing novel therapies for chronic and acute pain, raised $33M in Series B funding. The round was led by Schooner Capital with participation from SV Health ... |
| 14.05.2024 | Brixton Biosciences Secures $33M to Advance Novel Pain Therapies | Sameer Sabir, Chief Executive Officer of Brixton Biosciences What You Should Know: – Brixton Biosciences, a clinical-stage life sciences company focused on innovative pain treatments raises $33M in Series B funding led by Schooner Capital w... |
| - | Brixton Biosciences | “Neural Ice™ from Brixton Biosciences has the potential for long-last pain control from one injection. Intended to eradicate the pain of pain.” |